Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.
ASSOCIATION BETWEEN ANTIBODY TO ENVELOPE GLYCOPROTEIN GP120 AND THE OUTCOME OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION
Vaccines 88. New Chemical and Genetic Approaches to Vaccination: Prevention of AIDS and Other Viral, Bacterial, and Parasitic Diseases. Ginsberg H et al, eds. New York, Cold Spring Harbor Laboratory, p. 373-7, 1988.. Unique Identifier : AIDSLINE ICDB/89649784 Lee TH; Chou MJ; Huang JH; Yu XF; Allen J; McLane MF; Marlink R; Essex M; Redfield RR; Burke DS; et al; Dept. of Cancer Biology, Harvard Univ. Sch. of Public Health,; Boston, MA 02115
Abstract:
Several seroepidemiological studies are summarized with regard to response to gp120 antibody in HIV-infected individuals with different clinical manifestations, to determine if naturally produced gp120 antibodies correlated with the outcome of HIV infection. Two types of gp120-binding antibody occur: gp120(NR) and gp120(R). Analysis of gp120 antibodies produced in seropositive individuals suggests that gp120(NR) antibodies are directed to antigenic epitopes that are more immunogenic than those recognized by gp120(R) antibodies. The carboxyl portion of gp120 appears to contain epitopes recognized by gp120(R) antibody, as supported by the observation that almost all sera with gp120(R) reactivity recognize a gp120 recombinant peptide, designated gp120(343c), which covers the carboxyl portion of the gp120 sequence. This cross-sectional study revealed that HIV-seropositive individuals who were at later stages of infection were less likely to have gp120(R) antibody. The retrospective study showed that HIV-seropositive individuals who subsequently developed AIDS had a lower level of gp120(343c) than those who remained free of AIDS. Taken together, these results suggest that some naturally produced gp120 antibodies may influence the clinical outcome of HIV infection. Both those whose disease progressed and those whose disease did not progress (retrospective study) had comparable levels of gp120(NR) antibody, suggesting that this class of gp120-binding antibodies may not have a significant role in preventing disease progression. In light of the observation that antigenic domains recognized by gp120(NR) antibodies are immunogenically more dominant than those recognized by gp120(R), the possibility should be considered that a gp120 molecule in its most native conformation may not be the best choice for eliciting strong antibody response to gp120(R) or gp120(343c) epitopes in the high-risk population. (6 Refs)
Keywords: Acquired Immunodeficiency Syndrome/*IMMUNOLOGY Antibody Specificity Binding Sites, Antibody CD4-Positive T-Lymphocytes/IMMUNOLOGY Epitopes/IMMUNOLOGY Human HIV Antibodies/*BIOSYNTHESIS HIV Seropositivity/IMMUNOLOGY Prognosis Retroviridae Proteins/*IMMUNOLOGY MEETING PAPER
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.
